Cetuximab: its unique place in head and neck cancer treatment
P Specenier, JB Vermorken - Biologics: Targets and Therapy, 2013 - Taylor & Francis
Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …
Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck
J Bernier - Nature Clinical Practice Oncology, 2008 - nature.com
Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …
Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum …
JP Agarwal, T Gupta, N Kalyani… - Indian Journal of …, 2011 - journals.lww.com
Purpose: To report outcomes of cetuximab concurrent with radiotherapy in advanced head-
neck cancer unsuitable for platinum-based chemo-radiotherapy. Materials and Methods …
neck cancer unsuitable for platinum-based chemo-radiotherapy. Materials and Methods …
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a survival analysis of a Brown University Oncology Group phase II study
A Birnbaum, T Dipetrillo, R Rathore… - American journal of …, 2014 - journals.lww.com
Objectives: To assess the effect on progression-free and overall survival from the addition of
cetuximab to paclitaxel-based chemoradiation for patients with squamous cell head and …
cetuximab to paclitaxel-based chemoradiation for patients with squamous cell head and …
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced …
D Soulieres, JL Aguilar, E Chen, K Misiukiewicz… - BMC cancer, 2016 - Springer
Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …
A phase 2 open label, single-arm trial to evaluate the combination of cetuximab plus taxotere, cisplatin, and 5-flurouracil as an induction regimen in patients with …
R Mesía, S Vázquez, JJ Grau, JA García-Sáenz… - International Journal of …, 2016 - Elsevier
Purpose Despite treatment, prognosis of unresectable squamous cell carcinoma of the head
and neck (SCCHC) is dismal. Cetuximab therapy has proven to increase the clinical activity …
and neck (SCCHC) is dismal. Cetuximab therapy has proven to increase the clinical activity …
CetuGEX and cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): PK/PD results from the phase II RESGEX study.
H Baumeister, A Zurlo, J Fayette, B Dietrich, U Keilholz - 2018 - ascopubs.org
61 Background: Standard treatment for RM-HNSCC is a combination of cisplatin (P), 5-FU
(F), and the EGFR blocking monoclonal antibody (mAb) cetuximab (C). The mAb CetuGEX …
(F), and the EGFR blocking monoclonal antibody (mAb) cetuximab (C). The mAb CetuGEX …
Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN
MK Knoedler, T Gauler, A Matzdorff… - Journal of Clinical …, 2009 - ascopubs.org
6048 Background: Cetuximab and docetaxel are both active in squamous cell carcinoma of
the head and neck (SCCHN). We investigated the efficacy of cetuximab plus docetaxel as …
the head and neck (SCCHN). We investigated the efficacy of cetuximab plus docetaxel as …
[PDF][PDF] Should cetuximab replace cisplatin in head and neck cancer?
K Rowan - 2010 - academia.edu
On the other side of the debate, critics point to the limitations of this study, which did not
directly compare cetuximab to cisplatin, and the lack of any further phase III studies. They …
directly compare cetuximab to cisplatin, and the lack of any further phase III studies. They …